Zhao Yang, Yu Xiangrong, Li Jia
Centre for the Endothelium, Vascular Biology Program, Centenary Institute, The University of Sydney, Sydney NSW 2042, Australia.
Department of Radiology, Zhuhai People's Hospital, Jinan University, Zhuhai 519000, China.
Acta Pharm Sin B. 2020 Nov;10(11):2018-2036. doi: 10.1016/j.apsb.2020.09.014. Epub 2020 Sep 28.
Tumor vasculature is characterized by aberrant structure and function, resulting in immune suppressive profiles of tumor microenvironment through limiting immune cell infiltration into tumors, endogenous immune surveillance and immune cell function. Vascular normalization as a novel therapeutic strategy tends to prune some of the immature blood vessels and fortify the structure and function of the remaining vessels, thus improving immune stimulation and the efficacy of immunotherapy. Interestingly, the presence of "immune‒vascular crosstalk" enables the formation of a positive feedback loop between vascular normalization and immune reprogramming, providing the possibility to develop new cancer therapeutic strategies. The applications of nanomedicine in vascular-targeting therapy in cancer have gained increasing attention due to its specific physical and chemical properties. Here, we reviewed the recent advances of effective routes, especially nanomedicine, for normalizing tumor vasculature. We also summarized the development of enhancing nanoparticle-based anticancer drug delivery the employment of transcytosis and mimicking immune cell extravasation. This review explores the potential to optimize nanomedicine-based therapeutic strategies as an alternative option for cancer treatment.
肿瘤血管系统具有异常的结构和功能特征，通过限制免疫细胞浸润到肿瘤、内源性免疫监视和免疫细胞功能，导致肿瘤微环境的免疫抑制特征。血管正常化作为一种新的治疗策略，倾向于修剪一些不成熟的血管，并强化其余血管的结构和功能，从而改善免疫刺激和免疫治疗的疗效。有趣的是，“免疫-血管串扰”的存在使得血管正常化和免疫重编程之间形成正反馈回路，为开发新的癌症治疗策略提供了可能性。由于其特殊的物理和化学性质，纳米医学在癌症血管靶向治疗中的应用越来越受到关注。在此，我们综述了使肿瘤血管正常化的有效途径，尤其是纳米医学的最新进展。我们还总结了增强基于纳米颗粒的抗癌药物递送、跨细胞转运的应用以及模拟免疫细胞外渗的发展。本综述探讨了优化基于纳米医学的治疗策略作为癌症治疗替代选择的潜力。
